Cutaneous Toxicities: Management of irAEs Guideline (Part 3)
An interview with Dr. Milan Anadkat from Washington University & Dr. Aung Naing from MD Anderson Cancer Center, authors on "Management of Immune-Related Adverse Events in Patients Treated With Immune ...
2 Nov 202111min
CAR-T Cell Therapy: Management of irAEs Guideline (Part 2)
An interview with Dr. Bianca Santomasso from Memorial Sloan Kettering Cancer Center and Dr. Monalisa Ghosh from the University of Michigan Health System, authors on "Management of Immune-Related Adver...
1 Nov 202130min
ICPi Overview: Management of irAEs Guideline (Part 1)
An interview with Dr. Bryan Schneider from the University of Michigan Health System and Dr. Kathryn Bollin from Scripps MD Anderson Cancer Center, co-chairs of the Management of Immune-Related Adverse...
1 Nov 202113min
Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendation Update
An interview with Dr. Manish Shah from New York Hospital and Weill Cornell Medicine, co-chair on "Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendat...
18 Aug 20218min
Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
An interview with Dr. Nadine Tung and Dr. Dana Zakalik, co-chairs on "Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Here...
3 Aug 202115min
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Guideline Update
An interview with Dr. Harold Burstein from Dana Farber Cancer Institute in Boston, MA, chair on "Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast...
29 Jul 202116min
Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative Guideline Update
An interview with Dr. Beverly Moy from Massachusetts General Hospital, co-chair on "Chemotherapy and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-...
29 Jul 202111min
Telehealth in Oncology: Standards and Practice Recommendations
An interview with Dr. Robin Zon from Michiana Hematology Oncology in Mishawaka, IN, co-chair on "Telehealth in Oncology: ASCO Standards and Practice Recommendations." The standards address telehealth ...
28 Jul 202112min
